Summary

98.39 -0.69(-0.70%)05/20/2024
Cardinal Health, Inc. (CAH)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 YearsAll Time
1.23-3.18-8.84-5.53-3.0819.96137.8615,991.75


Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1


Trading Data
Close99.83
Open98.77
High99.91
Low98.73
Volume1,774,330
Change1.21
Change %1.23
Avg Volume (20 Days)1,908,038
Volume/Avg Volume (20 Days) Ratio0.93
52 Week Range80.90 - 116.04
Price vs 52 Week High-13.97%
Price vs 52 Week Low23.40%
Range1.07
Gap Up/Down-0.93
Fundamentals
Market Capitalization (Mln)24,133
EBIDTA2,783,000,064
PE Ratio44.0398
PEG Ratio0.3086
WallStreet Target Price113.50
Book Value-13.3810
Earnings Per Share2.2600
EPS Estimate Current Quarter1.9500
EPS Estimate Next Quarter1.8000
EPS Estimate Current Year7.3600
EPS Estimate Next Year7.5300
Diluted EPS (TTM)2.2600
Revenues
Profit Marging0.0025
Operating Marging (TTM)0.0107
Return on asset (TTM)0.0292
Return on equity (TTM)0.0000
Revenue TTM220,571,992,064
Revenue per share TTM891.2000
Quarterly Revenue Growth (YOY)0.0880
Quarterly Earnings Growth (YOY)-0.2160
Gross Profit (TTM)6,545,000,000
Dividends
Dividend Share2.0020
Dividend Yield0.0203
Valuations
Trailing PE44.0398
Forward PE13.4953
Price Sales (TTM)0.0000
Price Book (MRQ)16.0657
Revenue Enterprise Value 0.1189
EBITDA Enterprise Value13.5813
Shares
Shares Outstanding243,567,008
Shares Float242,268,740
Shares Short0
Shares Short (Prior Month)0
Shares Ratio0.00
Short Outstanding (%)0.00
Short Float (%)0.05
Insider (%)0.58
Institutions (%)91.33


05/17 10:01 EST - zacks.com
Investors Heavily Search Cardinal Health, Inc. (CAH): Here is What You Need to Know
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
05/13 10:46 EST - zacks.com
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
05/07 16:15 EST - prnewswire.com
Cardinal Health Board of Directors Approves Increase to Quarterly Dividend
DUBLIN, Ohio , May 7, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024.
05/06 17:02 EST - ndtv.com
Woman Discovers She Is A Male After Doctors Find Testicle In Her Stomach
Doctors found a testicle in her abdomen and diagnosed her with a rare disorder called Congenital Adrenal Hyperplasia (CAH)...
05/06 14:00 EST - investorplace.com
3 Stocks to Give You Shelter From the Coming Market Crash
Sometimes the best offense is a good defense. In today's market, buying defensive stocks is probably one of the best strategies you can adopt to protect your portfolio's gains.
05/06 10:01 EST - zacks.com
Here is What to Know Beyond Why Cardinal Health, Inc. (CAH) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.
05/03 07:19 EST - marketbeat.com
For Cardinal Health, the Proof Will be in Its Performance
Investors are familiar with the phrase "buy the rumor, sell the news." However, Cardinal Health Inc. NYSE: CAH proved that investors can buy and sell the news.
05/03 01:38 EST - seekingalpha.com
5 Expected Dividend Increases In May 2024
5 Expected Dividend Increases In May 2024
05/02 13:01 EST - zacks.com
Compared to Estimates, Cardinal (CAH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/02 12:17 EST - seekingalpha.com
Cardinal Health, Inc. (CAH) Q3 2024 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q3 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Matt Sims - VP, IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Lisa Gill - JP Morgan Michael Cherny - Leerink Partners George Hill - Deutsche Bank Allen Lutz - Bank of America Kevin Caliendo - UBS Eric Percher - Nephron Research Stephanie Davis - Barclays Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Stephen Baxter - Wells Fargo Lucas Romanski - TD Cowen Daniel Grosslight - Citi Operator Hello, and welcome to the Third Quarter Fiscal Year 2024 Cardinal Health Incorporated Earnings Conference Call. My name is George.
05/02 11:05 EST - zacks.com
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View
Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
05/02 08:52 EST - reuters.com
Cardinal Health lifts 2024 profit view on demand for costly specialty drugs
Cardinal Health raised its annual profit forecast on Thursday, betting on strength in its pharmaceutical unit selling costly specialty drugs used to treat complex conditions such as cancer.
05/02 07:08 EST - marketwatch.com
Cardinal Health's stock falls on mixed quarterly results
Cardinal Health Inc.'s shares CAH, -0.84% fell 1.2% premarket on Thursday after the company reported mixed results for its fiscal third quarter but raised its full-year profit outlook. The drug distributor and lab-equipment provider reported net income of $258 million, or $1.05 per share, down from $345 million, or $1.34 per share, in the year-earlier period.
05/02 06:45 EST - prnewswire.com
Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance
Revenue increased 9% to $54.9 billion GAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05 Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 Fiscal year 2024 non-GAAP EPS guidance 2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50 DUBLIN, Ohio , May 2, 2024  /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2024 revenues of $54.9 billion, an increase of 9% from the third quarter of fiscal year 2023. Third quarter GAAP operating earnings were $367 million and GAAP diluted earnings per share (EPS) were $1.05, which included a non-cash, pre-tax goodwill impairment of $90 million related to the Global Medical Products and Distribution (GMPD) segment as a result of the reallocation of goodwill related to the reporting structure update.
05/01 15:12 EST - investorplace.com
Shhh! 3 Secret Retirement Stocks Flying Below Wall Street's Radar
Investing for retirement can be one of the most essential steps to securing a future of overall financial stability. Nowadays, many investors need to start preparing a nest egg at a young age despite the idea of retirement seeming unnecessary.
04/29 13:10 EST - zacks.com
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
04/29 10:21 EST - zacks.com
Seeking Clues to Cardinal (CAH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Cardinal (CAH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
04/29 08:31 EST - seekingalpha.com
Apple, Cardinal Health Among 12 Companies To Announce Dividend Increases In First Half Of May
Apple, Cardinal Health Among 12 Companies To Announce Dividend Increases In First Half Of May
04/26 13:35 EST - zacks.com
Here's What You Should Know About EBAY Ahead of Q1 Earnings
EBAY's first-quarter 2024 performance will likely reflect strength across its advertising business amid softness in its active buyer base.